Brady Huggett signs off. Hosted on Acast. See acast.com/privacy for more information.

Brady Huggett signs off. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Good Bye

Jay Keasling

Jay Keasling is a professor in the College of Chemistry at the University of California at Berkeley, where he runs the Keasling lab. He’s also the CEO of the Joint BioEnergy Institute, and has been involved in several startups. His conversation with Nature Biotechnology covers growing up on the family farm in Nebraska, how Genentech led him into biotech, and the future of biofuels.  Hosted on Acast. See acast.com/privacy for more information.

Jay Keasling is a professor in the College of Chemistry at the University of California at Berkeley, where he runs the Keasling lab. He’s also the CEO of the Joint BioEnergy Institute, and has been involved in several startups. His conversation with Nature Biotechnology covers growing up on the family farm in Nebraska, how Genentech led him into biotech, and the future of biofuels. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Ingmar Hoerr is a co-founder and former CEO of CureVac. His conversation with Nature Biotechnology covers his initial discovery with RNA while in his PhD program, the struggle to find venture financing for CureVac, and how a brain aneurysm changed his view on life.   Hosted on Acast. See acast.com/privacy for more information.

Ingmar Hoerr is a co-founder and former CEO of CureVac. His conversation with Nature Biotechnology covers his initial discovery with RNA while in his PhD program, the struggle to find venture financing for CureVac, and how a brain aneurysm changed his view on life.  Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Ingmar Hoerr

Lita Nelsen

Lita Nelsen is the former long-time director of the Technology Licensing Office at the Massachusetts Institute of Technology. Her talk with Nature Biotechnology covers her father’s life designing television antennas, what drove her to the chemical engineering program at MIT, and the ingredients required to create an entrepreneurial environment on campus (and beyond). Hosted on Acast. See acast.com/privacy for more information.

Lita Nelsen is the former long-time director of the Technology Licensing Office at the Massachusetts Institute of Technology. Her talk with Nature Biotechnology covers her father’s life designing television antennas, what drove her to the chemical engineering program at MIT, and the ingredients required to create an entrepreneurial environment on campus (and beyond). Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Stan Crooke is born ⬩ A tenuous existence ⬩ Life with his mother ⬩ The Tech Corner ⬩ Arsenal Tech High School ⬩ Nancy ⬩ Hoodlum ways ⬩ Off to Purdue Hosted on Acast. See acast.com/privacy for more information.

Stan Crooke is born ⬩ A tenuous existence ⬩ Life with his mother ⬩ The Tech Corner ⬩ Arsenal Tech High School ⬩ Nancy ⬩ Hoodlum ways ⬩ Off to Purdue Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Hope Lies in Dreams Chapter 1

Anthony Atala

Anthony Atala is the director of the Institute for Regenerative Medicine at Wake Forest University. He is also a co-founder of Precise Bio. His conversation with Nature Biotechnology covers implanting the first tissue-engineered bladder into a patient, Wake Forest’s plans for fostering entrepreneurship, and how he was coerced into a research career by a mentor. Hosted on Acast. See acast.com/privacy for more information.

Anthony Atala is the director of the Institute for Regenerative Medicine at Wake Forest University. He is also a co-founder of Precise Bio. His conversation with Nature Biotechnology covers implanting the first tissue-engineered bladder into a patient, Wake Forest’s plans for fostering entrepreneurship, and how he was coerced into a research career by a mentor. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Nancy Simonian

Nancy Simonian is president and CEO of Syros Pharmaceuticals. Her conversation with Nature Biotechnology covers going against the advice of her mentor to take a job at Biogen; the long, winding path to approval for the multiple myeloma drug Velcade; and assisting her father in the operating room as a girl.  Hosted on Acast. See acast.com/privacy for more information.

Nancy Simonian is president and CEO of Syros Pharmaceuticals. Her conversation with Nature Biotechnology covers going against the advice of her mentor to take a job at Biogen; the long, winding path to approval for the multiple myeloma drug Velcade; and assisting her father in the operating room as a girl. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Carl June

Carl June is a co-founder of Tmunity Therapeutics, and a professor in immunotherapy at the University of Pennsylvania, where he also runs the June Lab. His conversation with Nature Biotechnology includes how a boyhood fractured arm led him to his first scientific experiment, his years of service with the Navy, and his groundbreaking work with CAR T-cells. Hosted on Acast. See acast.com/privacy for more information.

Carl June is a co-founder of Tmunity Therapeutics, and a professor in immunotherapy at the University of Pennsylvania, where he also runs the June Lab. His conversation with Nature Biotechnology includes how a boyhood fractured arm led him to his first scientific experiment, his years of service with the Navy, and his groundbreaking work with CAR T-cells. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Craig Mello

Craig Mello is co-founder of Atalanta Therapeutics and a professor at the University of Massachusetts Medical School, where he runs the Mello Lab. He is also a Nobel Laureate. His conversation with Nature Biotechnology covers the lure of conspiracy theorists, the state of RNA therapeutics, and getting that call from the Nobel committee.  Hosted on Acast. See acast.com/privacy for more information.

Craig Mello is co-founder of Atalanta Therapeutics and a professor at the University of Massachusetts Medical School, where he runs the Mello Lab. He is also a Nobel Laureate. His conversation with Nature Biotechnology covers the lure of conspiracy theorists, the state of RNA therapeutics, and getting that call from the Nobel committee.  Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Neil Kumar

Neil Kumar is a co-founder and CEO of BridgeBio Pharma. He discussed with Nature Biotechnology his youth in the Midwest, the founding principles behind BridgeBio, and understanding where your strengths lie. Hosted on Acast. See acast.com/privacy for more information.

Neil Kumar is a co-founder and CEO of BridgeBio Pharma. He discussed with Nature Biotechnology his youth in the Midwest, the founding principles behind BridgeBio, and understanding where your strengths lie. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future. Hosted on Acast. See acast.com/privacy for more information.

I’m an active biomedical researcher. I love how the interviewer ask common sense questions and also stick with the science/inspirations. Doing great, keep it going!

Great interview style

I listened to each episode twice.  Keep them coming!

Very insightful and well structured interviews!

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders

Nancy J Kelley, founder and chief executive of Nancy J Kelley + Associates, a consultancy creating and developing projects and institutions for science and medicine, touches on establishing the East River Science Park, excelling at Yale as a young mother of three and why one must take risks in life. Hosted on Acast. See acast.com/privacy for more information.

Nancy J Kelley, founder and chief executive of Nancy J Kelley + Associates, a consultancy creating and developing projects and institutions for science and medicine, touches on establishing the East River Science Park, excelling at Yale as a young mother of three and why one must take risks in life. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Nancy J Kelley

Una Ryan

Una Ryan discusses the biotech East Coast vs. West; life in Oxford, UK; and her initial foray into industry via a job at Monsanto. Hosted on Acast. See acast.com/privacy for more information.

Una Ryan discusses the biotech East Coast vs. West; life in Oxford, UK; and her initial foray into industry via a job at Monsanto. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Una Ryan

David Baltimore

David Baltimore, president emeritus of the California Institute of Technology, discusses his parents moving him from New York City to Great Neck, Long Island, as a child; his initial interest in animal virology; and getting that Nobel call from Sweden. Hosted on Acast. See acast.com/privacy for more information.

David Baltimore, president emeritus of the California Institute of Technology, discusses his parents moving him from New York City to Great Neck, Long Island, as a child; his initial interest in animal virology; and getting that Nobel call from Sweden. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: David Baltimore

George Yancopoulos

George Yancopoulos talks about the scientific foundation at Regeneron, upholding the family name and giving back through teaching. Hosted on Acast. See acast.com/privacy for more information.

George Yancopoulos talks about the scientific foundation at Regeneron, upholding the family name and giving back through teaching. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: George Yancopoulos

Cigall Kadoch

Cigall Kadoch is a co-founder of Foghorn Therapeutics and assistant professor at the Dana-Farber Cancer Institute, where she runs the Kadoch lab. In her talk with Nature Biotechnology, she discusses launching Foghorn, how geography affects biotech success, and the link between interior design and scientific rigor. Hosted on Acast. See acast.com/privacy for more information.

Cigall Kadoch is a co-founder of Foghorn Therapeutics and assistant professor at the Dana-Farber Cancer Institute, where she runs the Kadoch lab. In her talk with Nature Biotechnology, she discusses launching Foghorn, how geography affects biotech success, and the link between interior design and scientific rigor. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders: Cigall Kadoch

Samantha Du

Samantha Du is founder, CEO and chairman of Zai Lab. In her conversation with Nature Biotechnology she discusses her thoughts on the US-China trade war, what makes Zai Lab a success, and her family's experience during the Cultural Revolution in China. Hosted on Acast. See acast.com/privacy for more information.

Samantha Du is founder, CEO and chairman of Zai Lab. In her conversation with Nature Biotechnology she discusses her thoughts on the US-China trade war, what makes Zai Lab a success, and her family's experience during the Cultural Revolution in China. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders: Samantha Du

Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results. Hosted on Acast. See acast.com/privacy for more information.

Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Jeremy Levin

Colin Goddard

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover. Hosted on Acast. See acast.com/privacy for more information.

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Colin Goddard

Stephen Quake

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced. Hosted on Acast. See acast.com/privacy for more information.

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Stephen Quake

James Wilson

James Wilson is the director of the Gene Therapy Program at the University of Pennsylvania. He is also a founder and chief scientific advisor at Regenx Bio, as well as founder and chairman of scientific advisory council at Dimension Therapeutics. Wilson's conversation covers his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing. Hosted on Acast. See acast.com/privacy for more information.

James Wilson is the director of the Gene Therapy Program at the University of Pennsylvania. He is also a founder and chief scientific advisor at Regenx Bio, as well as founder and chairman of scientific advisory council at Dimension Therapeutics. Wilson's conversation covers his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: James Wilson

Michael West

Nature Biotechnology talked to West about his initial love for physics, scoring the first funding for Geron and the future of regenerative medicine. Hosted on Acast. See acast.com/privacy for more information.

Nature Biotechnology talked to West about his initial love for physics, scoring the first funding for Geron and the future of regenerative medicine. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders: Michael West

Anthony Davies discusses the past, present and future of stem cell therapies. Hosted on Acast. See acast.com/privacy for more information.

Anthony Davies discusses the past, present and future of stem cell therapies. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder:  Focus issue podcast

Pardis Sabeti

Pardis Sabeti is a co-founder of Sherlock Biosciences, the head of the Sabeti Lab, and a co-author of Outbreak Culture. Her conversation with Nature Biotechnology covers her family fleeing the Iranian revolution, the Sabeti Lab's role in the Ebola outbreak of 2014-2016, and the ATV accident that nearly killed her. Hosted on Acast. See acast.com/privacy for more information.

Pardis Sabeti is a co-founder of Sherlock Biosciences, the head of the Sabeti Lab, and a co-author of Outbreak Culture. Her conversation with Nature Biotechnology covers her family fleeing the Iranian revolution, the Sabeti Lab's role in the Ebola outbreak of 2014-2016, and the ATV accident that nearly killed her. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders: Pardis Sabeti

Alexis Borisy

Alexis Borisy is CEO and Chairman of EQRx, and a long-time biotech builder with Third Rock Ventures. His conversation with Nature Biotechnology covers growing up as a “faculty brat” in Wisconsin, dropping out of his PhD program at Harvard and why, even as an investor, biotech cannot be all about the money.  Hosted on Acast. See acast.com/privacy for more information.

Alexis Borisy is CEO and Chairman of EQRx, and a long-time biotech builder with Third Rock Ventures. His conversation with Nature Biotechnology covers growing up as a “faculty brat” in Wisconsin, dropping out of his PhD program at Harvard and why, even as an investor, biotech cannot be all about the money.  Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Nina Tandon

Nina Tandon is co-founder and CEO of EpiBone. Her First Rounders conversation covers growing up on Roosevelt Island in New York City, witnessing September 11, and tackling her company's first Phase 1 trial. Hosted on Acast. See acast.com/privacy for more information.

Nina Tandon is co-founder and CEO of EpiBone. Her First Rounders conversation covers growing up on Roosevelt Island in New York City, witnessing September 11, and tackling her company's first Phase 1 trial. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounders: Nina Tandon

Daphne Zohar

Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital. (Updated February 6, 2015). Hosted on Acast. See acast.com/privacy for more information.

Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital. (Updated February 6, 2015). Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Daphne Zohar

Carl Feldbaum

Carl Feldbaum was the founding president of the Biotechnology Industry Organization (BIO), and he is the current chairman of the Life Sciences Foundation. His podcast conversation with Nature Biotechnology touches on his assistance in prosecuting Watergate, his visit to Saddam Hussein's palace and how he built BIO from the ground up. Hosted on Acast. See acast.com/privacy for more information.

Carl Feldbaum was the founding president of the Biotechnology Industry Organization (BIO), and he is the current chairman of the Life Sciences Foundation. His podcast conversation with Nature Biotechnology touches on his assistance in prosecuting Watergate, his visit to Saddam Hussein's palace and how he built BIO from the ground up. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Carl Feldbaum

Kari Stefansson

Kari Stefansson's conversation with Nature Biotechnology covers the founding of deCODE, his love for literature (and his favorite poet), plus his encounter with the tortured chess grandmaster Bobby Fischer. Hosted on Acast. See acast.com/privacy for more information.

Kari Stefansson's conversation with Nature Biotechnology covers the founding of deCODE, his love for literature (and his favorite poet), plus his encounter with the tortured chess grandmaster Bobby Fischer. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Kari Stefansson

Rachel King

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens. Hosted on Acast. See acast.com/privacy for more information.

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Rachel King

Stan Crooke

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader. Hosted on Acast. See acast.com/privacy for more information.

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

First Rounder: Stan Crooke

What is this?
1 quote, 3 ideas & 1 question from a carefully curated podcast episode.
Every Monday & Wednesday.

Want a 3rd insight and episode every week? Email me at curation@owltail.com.

OwlTail

OwlTail 1-3-1

The Best Multi-Part Documentaries, with documentaries on Obama, Federer vs Nadal, the making of Star Wars, Netflix vs Blockbuster and more. Add episodes you're interested into your queue below!